Enhanced alveolar macrophage Ia antigen expression after asbestos inhalation.
D000281:Administration, Intranasal; D000818:Animals; D001194:Asbestos / Q000008:administration & dosage / Q000494:pharmacology*; D017638:Asbestos, Crocidolite; D017632:Asbestos, Serpentine; D001195:Asbestosis / Q000276:immunology; D005260:Female; D000949:Histocompatibility Antigens Class II / Q000276:immunology*; D008264:Macrophages / Q000187:drug effects / Q000276:immunology*; D008297:Male; D010587:Phagocytosis / Q000187:drug effects; D011650:Pulmonary Alveoli / Q000166:cytology; D051381:Rats; D011912:Rats, Inbred ACI; D011916:Rats, Inbred F344
D017632:Asbestos, Serpentine; D000949:Histocompatibility Antigens Class II; D017638:Asbestos, Crocidolite; D001194:Asbestos